tildrakizumab
Selected indexed studies
- Tildrakizumab. (, 2012) [PMID:31643619]
- Tildrakizumab for the treatment of psoriasis. (Expert Rev Clin Immunol, 2019) [PMID:30394141]
- Tildrakizumab. (, 2006) [PMID:30000026]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tildrakizumab. (2012) pubmed
- Tildrakizumab for the treatment of psoriasis. (2019) pubmed
- Tildrakizumab. (2006) pubmed
- Tildrakizumab for psoriasis. (2019) pubmed
- Tildrakizumab for the treatment of psoriasis. (2018) pubmed
- Tildrakizumab (Ilumya®). (1994) pubmed
- Tildrakizumab for Moderate-to-Severe Plaque Psoriasis. (2019) pubmed
- Tildrakizumab: A Review of Phase II and III Clinical Trials. (2019) pubmed
- Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis. (2019) pubmed
- Tildrakizumab: First Global Approval. (2018) pubmed